Aims Acute graft-versus-host disease (aGVHD) is a leading cause of morbidity and mortality following allogeneic haematopoietic stem cell transplantation (HSCT). The aim of this study was to evaluate the clinical utility of a composite biomarker panel to help identify individuals at risk of developing aGVHD, and to help predict and differentiate between severity of aGVHD following T-cell-depleted allogeneic HSCT. Methods We retrospectively analysed our cohort of biopsy confirmed patients with aGVHD, who underwent T-cell-depleted HSCT and matched them with negative controls without any evidence of aGVHD. Post-transplant serum samples on days 0 and 7 and at onset of aGVHD were analysed for elafin, regenerating islet-derived 3-α, soluble tumour necrosis factor receptor-1, soluble interleukin-2 receptor-α and hepatocyte growth factor. Biomarker data were combined as composite panels A-F (table 2) using logistic regression analysis. Receiver operating characteristic analysis was performed to study sensitivity and specificity of the composite panels. Results Our composite biomarker panels significantly differentiated between aGVHD and no GVHD patients at time of onset ( panel E) and reliably predicted severity of GVHD grades at days 0 and 7 post-transplant ( panels B and D). The area under the curve for the composite panel at time of onset was 0.65 with specificity, sensitivity, positive and negative predictive values of 100%, 55.6%, 100% and 78.9%, respectively ( p=0.03). Conclusions This pilot data support the usefulness of these composite biomarker panels in the prediction of severity and diagnosis of aGVHD in patients undergoing T-cell-depleted reduced intensity allogeneic HSCT.
INTRODUCTION
Allogeneic haematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for a range of malignant and non-malignant haematological diseases. However, its use is limited by several complications including aberrant immune response by alloreactive T cells causing acute and chronic graft-versus-host disease (GVHD). The incidence of GVHD varies enormously from 10% to 80% depending on risk factors such as degree of human leucocyte antigen disparity, graft source, conditioning regimen (standard myeloablative or reduced intensity, with or without T-cell depletion), cytomegalovirus serostatus, recipient age, GVHD prophylaxis regimen, donor parity and sex mismatch. [1] [2] [3] [4] [5] [6] The diagnosis of acute GVHD (aGVHD) remains mainly clinical, supplemented by biopsy where possible. 7 8 The skin is the most commonly involved organ and presentation can range from a limited maculopapular rash on the palms and soles to widespread skin involvement with mucocutaneous ulceration and bullae formation. Similarly, other organs such as gastrointestinal (GI) tract and liver can be involved and the symptoms range from mild to severe. Histology can be helpful but the findings are often non-specific. 9 Currently, there are no established biomarkers that can reliably diagnose, assess prognosis or have any target organ specificity of aGVHD. 10 11 However, important advances have been made in biomarker biology with potential clinical applications in aGVHD settings. 11 Hepatocyte growth factor (HGF) is a cytokine secreted by the mesenchymal cells as a physiological response to hepatic and intestinal damage and significantly higher concentrations were found in patients who developed severe aGVHD. 12 Soluble tumour necrosis factor alpha (TNFα) concentrations are higher in patients with aGVHD and positively correlated with its severity in some studies [13] [14] [15] [16] whereas other studies did not support this relationship. 5 13 17 18 Soluble TNF receptor 1 (sTNFR1) is present in nanogram concentrations in a very stable state 13 and has been associated with severity of aGVHD in most studies. 5 19 20 Increased sTNFR1 at day 7 after HSCT was associated with the severity of GVHD and treatmentrelated mortality. 19 21 Activated donor T cells express interleukin 2 receptor (IL-2R), which contains three subunits α, β and γ, on their cell membrane. 22 23 IL-2 binds to the β-subunit and is subsequently internalised and the α-subunit is shed from the cell surface and found in plasma as soluble interleukin-2 receptor-α (sIL-2Rα). 23 24 Increased sIL-2Rα concentrations were noted in patients with aGVHD and closely correlated with GVHD severity. 11 25 26 Regenerating islet-derived 3-α (REG3α) is an antimicrobial protein secreted by Paneth cells 27 and a promising biomarker of lower GI aGVHD. Elafin is an elastase inhibitor overexpressed in inflamed epidermis 28 29 and is induced by inflammatory cytokines that mediate GVHD. 20, 30 Increased elafin concentrations were noted at the onset of cutaneous aGVHD and closely correlated with aGVHD severity. It was also noted as a prognostic marker because of its association with non-relapse mortality (NRM) and overall survival (OS). 30 These biomarkers have been studied in the context of T-cellreplete allogeneic HSCT but data are lacking in the T-celldepleted setting. The aim of this study was to evaluate the clinical utility of composite biomarker panel consisting of HGF, elafin, sIL-2Rα, sTNFR1 and REG3α in T-cell-depleted allogeneic HSCT.
METHODS

Study population
This study is a retrospective analysis of a subset of patients with allogeneic HSCT from the invasive aspergillosis study by Ceesay et al 31 (ClinicalTrials.gov No. NCT00816088; REC no: 08/ HA0808/154) with full ethical approval. Patients were included if they had biopsy-confirmed diagnosis of aGVHD within 100 days of transplantation. These patients were then matched (age, sex, underlying haematological diagnosis, time since transplant and conditioning regimen) with other allogeneic HSCT recipients who had no evidence of aGVHD. A total of 26 patients were included in the current study (12 confirmed aGVHD and 14 matched negative controls). Grading of aGVHD was according to Modified Seattle Glucksberg criteria. 8 Transplant conditioning protocols were either alemtuzumab or antithymocyte globulin (ATG)-based (in vivo T-cell depletion) regimens. None of the patients had any evidence of infection at the time of sample collection.
Blood samples and biomarker measurements
Serum samples at days 0 and 7 post-transplant and at the time of onset of aGVHD were evaluated for the biomarker panel (HGF, elafin, sIL-2Rα, sTNFR1 and REG3α). HGF, sTNFR1 and sIL-2Rα were analysed using ELISA methods from R&D Systems (Abingdon, Oxfordshire, UK). Elafin was measured using an ELISA method from Abcam (Cambridge, UK) and REG3α was measured using an ELISA method from Cloud-Clone (Yuhan, China). The assays for purpose of this study were carried out using ELISA plates for five biomarkers on three different days in duplicates with standard internal quality control to limit interassay variation, corresponding to samples from day 0, day 7 post-HSCT and at time of aGVHD onset in batches. The methods used for estimation of these biomarkers were internally validated before using them to measure clinical patients' samples. All patient samples were run in duplicate and coefficient of variance between duplicate samples was <10%. All method validation studies including precision, linearity, recovery, stability, carry over/under and lower limit of detection were duly carried out.
Each of these results performed in the study was reviewed by clinical biochemists following internal laboratory validation; median results were reviewed and correlated with clinical picture of the study patients following sample collection, although limited by retrospective nature of the study.
Statistical analysis
Statistical analysis including receiver operating characteristic (ROC) analysis was performed using Analyse-It V.2 (Leeds, UK). Data were tested for normality using the Shapiro-Wilk W test with a CI of 95%. Patient characteristics were compared by the χ 2 test or the Mann-Whitney U test.
Logistic regression was performed using SigmaXL V.7 (Kitchener, Canada) to develop a composite panel of biomarkers (panels A-F; table 1). Binary logistic regression was used for a composite panel to discriminate between no GVHD and GVHD biopsy-positive patients. Ordinal logistic regression was used to develop a composite panel for differentiating grading of GVHD. The best three markers with most significant p value were included to produce the best fit model.
Each equation of the composite panels differs based on different time points of samples analysed, grade of aGVHD and dependent on statistically significant coefficient estimates of each panel. Numerical data were reported as median and IQR. A p value ≤ 0.05 was taken as statistically significant using logistical regression modelling.
To evaluate the reproducibility of the accuracy obtained in the composite panel and uncertainty around it, we conducted bootstrap (random subsampling from the same underlying population) cross-validation with 1000 replications to determine 95% CI for the area under the curve (AUC).
ROC analysis was performed to evaluate the sensitivity and specificity of the composite panel at time of aGVHD onset. ROC curves at days 0 and 7 post-transplant could not be carried out because of the small sample size.
RESULTS
Baseline characteristics of patients with aGVHD were similar to the negative controls (table 1). All aGVHD cases had cutaneous involvement except one who had GI pathology (grade II) only. Six other patients had combined cutaneous and GI aGVHD (grades II-IV). The median time to aGVHD onset was 31 (range 12-77) days.
Each of the composite biomarker panels was evaluated for their diagnostic utility of differentiating between no GVHD and biopsy-positive aGVHD patients and correlate grading of disease severity on samples taken at day 0, 7 and time of onset of GVHD post-transplant. Panel A (elafin + sIL-2R + sTNFR1) and panel C (elafin + HGF + REG3) at days 0 and 7 post-transplant respectively could not differentiate between aGVHD and no GVHD cases.
Composite panel E (elafin + sIL-2Rα + REG3α) measured at onset of aGVHD could differentiate between aGVHD and no GVHD patient groups (table 2A, C, E).
The composite panels B and D differentiated between severity of aGVHD (grades III and IV) and no GVHD patients at days 0 and 7 post-transplant, respectively ( p<0.01). Composite panel F also categorised the grading of aGVHD at time of onset; no aGVHD versus grade I ( p=0.02), no aGVHD versus grade II ( p<0.01), no aGVHD versus grades III and IV aGVHD ( p<0.01) (table 2B, D, F).
ROC curve analysis was undertaken to evaluate specificity and sensitivity of this panel. The AUC for this panel at time of aGVHD onset was 0.73 (CI 50% to 70%, p=0.03) with specificity, sensitivity, positive predictive value (PPV) and negative predictive value (NPV) of 100%, 55.6%, 100% and 78.9% respectively, suggestive of a diagnostic utility for the panel (table 3 and figure 1) .
DISCUSSION
In our pilot study, we have demonstrated the usefulness of composite biomarker panels in the prediction of severity and diagnosis of aGVHD in patients undergoing T-cell-depleted reduced intensity allogeneic HSCT. A number of small studies have investigated multiple proteins as individual potential biomarkers; 20 however, none has been validated as a composite diagnostic panel or predictive laboratory test for aGVHD to date and there have been no validations of these biomarkers in the T-cell-depleted HSCT. Chen et al 32 identified characteristics of candidate biomarkers that should allow (1) ease of testing, (2) a widely available technique with good reproducibility, (3) relatively low cost, (4) adequate sensitivity with high specificity, (5) predictive value, (6) correlation with severity and (7) correlation with treatment response.
There are only few published papers focusing on a composite biomarker panel for aGVHD and most were studied in non-T-cell-depleted allograft patients. Paczesny et al 20 developed a four biomarker panel using HGF, sIL-2Rα, IL8 and sTNFR1 with potential diagnostic utility in patients at onset of aGVHD and provide prognostic information independent of aGVHD severity. August et al 33 reported that a panel of three biomarkers including sIL-2 Rα, sTNFR1 and soluble CD8 is the best Table 2 Comparison of composite biomarker panels (A-F) utility in diagnosis and predicting severity of aGVHD in T-cell-depleted HSCT patients Online supplementary panels A-F. aGVHD, acute graft-versus-host disease; haematopoietic; HGF, hepatocyte growth factor; HSCT, haematopoietic stem cell transplantation; REG3α, regenerating islet-derived 3-α; sIL-2Rα, soluble interleukin-2 receptor-α; sTNFR1, soluble tumour necrosis factor receptor-1. screening test with an AUC of 0.77 at day 15 post-transplant. Levine et al 34 developed the Ann Arbor scoring system based on a composite panel using ST2 (suppression of tumorigenicity-2), sTNFR1 and REG3α with potential to predict the development of GI aGVHD. Simultaneous use of several biomarkers may increase specificity and hence diagnostic and/or predictive values for aGVHD. Combination of tissue-specific and systemic biomarkers is likely to be more informative than single biomarkers for aGVHD diagnosis.
The utility of composite panel in patients with HSCT is further evident by ROC curve analysis of composite biomarkers in panel E with specificity of 100% and sensitivity of 55.6%, at time of aGVHD onset. Depending on specific clinical situation, the sensitivity and specificity of the panel can be adjusted using ROC curve analysis and reference ranges for composite biomarkers could be derived. 33 For example, the sensitivity of the panel improves to 66.7% with specificity of 86.7% providing PPV of 75.0% and NPV of 81.2% for diagnosis ( figure 1) . Thus, composite biomarkers in panel E, measured at time of onset of aGVHD, significantly differentiated between no GVHD and biopsy-positive aGVHD group (all grades) in contrast to panels A and C measured at days 0 and 7 post-HSCT. This highlights its potential use as an alternative diagnostic tool for aGVHD with an added convenience of non-invasive sampling to patients.
Promisingly, composite biomarker panel B and panel D analysed at days 0 and 7 post-transplant in our pilot study were also able to predict severity of grades III and IV aGVHD before onset. These panels could potentially serve as an important laboratory tool for pre-emptive modification of immunosuppressive therapy at an earlier stage and reduce associated morbidity with severe aGVHD. Our combined biomarker panel F was also able to accurately predict between all grades of aGVHD at time of onset, which could be useful for identifying potential low-risk patients (mild-to-moderate aGVHD) and predict prognosis from aGVHD-related morbidity.
Very limited evidence exists for evaluation of similar biomarkers in patients with 'biopsy-proven' aGVHD and previous studies predominantly included patients who received nonmanipulated or T-cell-depleted allogeneic HSCT. T-cell depletion with drugs like alemtuzumab results in subdued immune responses to inflammation with increase in homeostatic regulatory T cells and decrease in proinflammatory cytokines. 35 Any biomarker assay based on proinflammatory proteins in this setting may not correlate well with diagnosis of aGVHD in theory, thus forming our basis of null hypothesis for this study. This is the first reported study within T-cell-depleted allogeneic HSCT settings and despite the potential anti-inflammatory effects of the conditioning regimen, we could reliably report potential clinical utility of a composite biomarker panel in diagnosis of aGVHD in these patients, who otherwise required biopsy for diagnosis.
From an economical perspective, elafin and REG3α costs €21 per test and sTNFR1, HGF, sIL-2Rα analysis cost €14 per test in our centre. Therefore, a composite panel using three biomarkers will cost around €55 which is considerably cheaper and cost-effective than combined costs of diagnostic tissue biopsy (operator time and skills, tissue processing and reporting); while removing, the risks associated with invasive procedures in this immunocompromised patient population. Currently, these assays are available as research only tests in our centre, but performed by state registered biomedical scientists working in NHS laboratories, however not accredited or part of any external quality assessment exercise or sample exchange programme. The use of these assays, once validated in larger cohort of clinical samples in a prospective study, can be implemented by most accredited laboratories familiar with automated ELISA methods run by state registered appropriately trained staff.
The assay is limited by its relatively labour intensive technique and need for minimum number of samples, which can potentially dictate frequency of samples run in clinical laboratory practice. This can be reduced by full automation and performed in larger regional diagnostic reference centres for cost-effective operation.
Our study is however limited by the small number of patients. Due to the retrospective nature of this study, we could not study composite biomarker trends to assess any correlation with severity of disease, subsequent response to therapy and its impact on survival. This would be an interesting research question in a larger prospective study and could help answer its usefulness in serial measurements of biomarkers to help guide withdrawal of immunosuppression.
CONCLUSION
The use of composite panels is more useful than individual markers. This is again demonstrated with panels of composite biomarker proposed in this pilot study, providing an improvement in the sensitivity and specificity of diagnosis of aGVHD as well as predicting disease severity in T-cell-depleted HSCT. Larger studies are still required to validate their findings and assess its potential impact on NRM and OS with early aGVHD diagnosis.
Take home messages
▸ Acute graft-versus-host disease (aGVHD) is an unpredictable and potentially debilitating complication of allogeneic haematopoietic stem cell transplants (HSCT). No validated diagnostic blood test for aGVHD currently exists, although multiple blood proteins have been described as potential biomarkers of aGVHD, mainly in HSCT treated with T-cell-replete conditioning regimens. ▸ Composite serum biomarker panels developed using logistic regression modelling of hepatocyte growth factor, elafin, soluble interleukin-2 receptor-α , soluble tumour necrosis factor receptor-1 and regenerating islet-derived 3-α, in this retrospective pilot study of T-cell-depleted HSCTs reported for the first time, successfully predicted severe aGVHD at early time points of days 0 and 7 post-transplant and diagnosed onset of aGVHD with a high positive and negative predictive value. ▸ The use of composite panels is more useful than individual markers. Once validated in larger prospective studies, these composite biomarker panels can be potentially used as an alternative diagnostic tool for aGVHD, with an added convenience of cost-effective non-invasive sampling, and an important laboratory tool for pre-emptive modification of immunosuppressive therapy at an earlier stage and reduce associated morbidity with severe aGVHD.
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